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Background: Dystonia is a hyperkinetic movement disorder related to dysfunction of inhibitory basal ganglia and
cortical circuits. GABA is the major inhibitory neurotransmitter in the central nervous system. Quinolones can rarely
produce serious neurologic effects, which have been attributed to impaired inhibition through GABA antagonism.
We report a case of reversible craniocervical dystonia associated with oral levofloxacin.
Case presentation: A 62-year-old man on hemodialysis presented with craniocervical dystonia 3 days after initiation
of levofloxacin 500 mg. twice daily. Levofloxacin was discontinued. Seven days later the abnormal movements
completely disappeared and did not recur in the following 3 months.
Conclusion: Levofloxacin should be considered as a rare but potentially reversible trigger of craniocervical dystonia.
Older age, renal impairment and high doses of the drug might be risk factors.
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Dystonia is a hyperkinetic movement disorder character-
ized by typically patterned, sustained or intermittent
muscle contractions producing abnormal, often repeti-
tive, movements, postures, or both. It is often precipi-
tated or worsened by voluntary action and associated
with overflow muscle activation [1]. Defective inhib-
ition in basal ganglia and cortical pathways are
thought to play a significant role in the pathophysi-
ology of dystonia [2].
Quinolones have γ-aminobutyric acid (GABA) type-A
receptor antagonist properties [3], and can thus impair
inhibition and act as excitatory compounds in central
nervous system (CNS) circuits. They have been rarely re-
ported to cause abnormal hyperkinetic movement disor-
ders. These reactions have been particularly described in
patients taking ciprofloxacin, the quinolone with the
most potent GABA antagonist effect [3,4].
We report a case of reversible craniocervical dystonia
associated with oral levofloxacin therapy in an end-stage
renal disease (ESRD) patient on hemodialysis (HD).* Correspondence: klizarraga@med.miami.edu
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A 62-year-old, left-handed, Caucasian man undergoing
HD every-other-day due to diabetes mellitus related
ESRD, presented with intermittent episodes of involun-
tary blinking, speech stuttering and neck flexion on
attempted oral communication. These episodes were
particularly severe with stress or anxiety. Patient denied
a preceding urge to move or talk. Patient denied oscil-
lopsia, diplopia, ear clicking, tinnitus, dysphagia or hallu-
cinations. There was no history of prior exposure to
dopamine-blocking medications or quinolones. Patient
was compliant with multiple medications for diabetes
mellitus and ESRD. Three days prior to the onset of ab-
normal movements, patient had been empirically pre-
scribed levofloxacin 500 mg. orally twice daily for
urinary symptoms. No other medication had been re-
cently added or discontinued, and there was no recent
dose change on his usual medications. There was no
family history of abnormal movements.
On examination, the patient was alert and fully ori-
ented. Dystonic movements of upper facial, oromandibu-
lar and cervical muscles causing involuntary blinking,
blepharospasm, tongue tremor and protrusion, dysarthria,
platysmata contractions and anterocollis were observed.
Bilateral ocular and palatal movements were normal with-
out motor impersistence on voluntary tongue protrusional. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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muscle weakness. There were no other associated abnor-
mal movements including limb dystonia, chorea or par-
kinsonism. There were no upper motor neuron or
cerebellar signs.
Laboratory studies disclosed stable values in complete
blood count and comprehensive metabolic panel includ-
ing electrolytes and renal function tests (creatinine level
range: 3.8–5.1 mg/dL). Urine culture was negative. No
imaging studies were obtained.
Levofloxacin was discontinued and patient noted pro-
gressive improvement in the duration and severity of the
dystonic episodes. Seven days later they had completely
disappeared [Additional file 2: Video 2]. Furthermore,
there were no more episodes in the following 3 months.
Discussion
According to recent guidelines, we use the term craniocer-
vical dystonia instead of the eponym “Meige syndrome” to
describe this patient’s intermittent episodes of involuntary
blinking, blepharospasm, tongue protrusion, platysmata
contractions and anterocollis ([1,5], Additional file 1:
Video 1). Most of these movements were observed when
he attempted to talk and were not preceded by an intense
urge to move or talk. Tongue tremor at rest and patterned
episodes of tongue protrusion while maintaining an open
mouth were noted [Additional file 1: Video 1]. In fact, dys-
tonic tremor has been described as inconstant and often
exacerbated by an attempt to maintain posture [6]. Finally,
this patient did not complain of dysphagia and there were
no abnormal movements of the jaw.
In patients with craniocervical dystonia, an 11% chance
of spontaneous remission has been reported, particularly
those with blepharospasm [7]. Yet, it is important to iden-
tify potentially reversible causes.
Fluoroquinolones are commonly used antibiotics that
can have CNS excitatory effects through a dose-dependent,
GABA-A receptor antagonist mechanism [3,4]. Ciprofloxa-
cin has been shown to be a more potent GABA antagonist
than other quinolones in vitro [3]. Moreover, an in vivo
EEG study demonstrated pronounced decrease in delta
and theta, as well as augmentation of alpha wave bands
after ofloxacin infusion. These effects were augmented by
flumazenil and reversed by midazolam [4]. In general,
quinolones are rarely associated with neurological adverse
reactions, mostly dizziness, headache and insomnia. They
have a <0.5% rate of serious neurological reactions includ-
ing abnormal movements, alteration of consciousness and
epileptic spells. However, ciprofloxacin has a rate of up to
4% [8-10]. New agents are developed by chemically modi-
fying older compounds to improve their spectrum, po-
tency, pharmacokinetics and safety. Levofloxacin, derived
from ofloxacin, received marketing approval in the US in
1997. Remarkably, the recommended dose of levofloxacinis equivalent to a 2.5 times higher ofloxacin dose. Levoflox-
acin has a <0.001% rate of severe neurologic reactions,
mostly reported as convulsions [8-10].
A diverse reversible hyperkinetic movement phenom-
enology has been reported in relation to ciprofloxacin
(tremor [9,11], myoclonus [12-14], orofacial dyskinesias
[15,16], chorea [17], tic disorder [18], palatal tremor
[19] and stereotypy [17]), levofloxacin (tremor and cho-
rea [20]), ofloxacin (tic disorder [21]) and gemifloxacin
(dystonia [22]).
The pathophysiology of dystonia encompasses dysfunc-
tion of inhibitory basal ganglia and cortical circuits [2].
Through GABA antagonism, quinolones could potentially
predispose to abnormal inhibition and trigger dystonic
movements. To the best of our knowledge, dystonia has
not been reported in association with levofloxacin. Add-
itionally, segmental dystonia has not been described as a
side effect of quinolones.
A case of acute-onset multifocal dystonia (involving
the four extremities with sparing of axial muscles) has
been reported in a 36 year-old woman three days after
initiation of gemifloxacin. Her abnormal movements
quickly resolved with intravenous administration of pro-
methazine 50 mg [22]. A 43 year-old woman presented
with confusional state, “dystonic posturing of the feet”,
diffuse chorea and stereotypy preceding generalized
tonic-clonic seizures after ciprofloxacin intake [17]. In
another report, a 49 year-old woman was noted to have
intermittent 1-hour episodes of facial grimacing every
4–6 hours that were described as “oral facial dyskinesia”
induced by ciprofloxacin [15], but may have included
blepharospasm. Finally, a 68 year-old man taking cipro-
floxacin was noted to have 15–30 second episodes of
“orofacial dyskinesias” consisting of facial grimacing and
distortions, puckering and pursing of the lips, without
eyelid involvement. These episodes resolved shortly after
ciprofloxacin was discontinued [16].
Levofloxacin is excreted primarily unchanged in urine
[23]. Therefore, dose adjustments are required in indi-
viduals with impaired renal function. HD does not ef-
fectively remove the drug from the body [24]. Dosing
guidelines recommend 500 mg on the first day,
followed by 250 mg every 48 hours for patients with
ESRD on HD [25]. Our patient, an older ESRD patient
on HD, was taking 500 mg twice daily for 3 days before
dystonia onset.
As hypothesized in other reports, neurotoxic levels of
levofloxacin were likely reached due to a combination of
renal impairment, age-related decline in cerebral func-
tion and reduction of plasma volume leading to higher
plasma and CNS drug concentrations. Similar to other
reported cases of quinolone-associated hyperkinetic
movements, dystonia disappeared completely after dis-
continuation of levofloxacin [Additional file 2: Video 2].
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considered to reverse the GABA inhibition related to
quinolone intoxication [26]. Due to the ethical implica-
tions of a “quinolone challenge”, it was felt that the time
course of the patient’s dystonia in relation to levofloxa-
cin intake and discontinuation was a strong evidence for
this association.
Conclusion
Levofloxacin should be considered as a rare but poten-
tially reversible cause of new-onset craniocervical dys-
tonia, particularly in older adults with renal impairment.
High doses, older age and renal impairment might be
risk factors for this side effect.
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for publication of this case report and any accompanying
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days after discontinuation of levofloxacin.
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